Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually…
Income investors own Gilead Sciences (NASDAQ:GILD | GILD Price Prediction) for the check that lands every quarter. That check just got bigger, and the question is whether the biology behind it can keep it coming.
Gilead’s board declared a quarterly dividend of $0.82 per share on July 28, 2026, with an ex-dividend date of September 15, 2026 and a payment date of September 29, 2026. On a trailing twelve month basis, the payout runs to $3.22 per share. With shares closing at $151.22 on September 3, 2026, that translates into a dividend yield of 0.0215 as reported.
The stock itself has already done the heavy lifting for total return this year, rising 24.72% year to date and 37.33% over the past year. For a retiree focused on income, coverage matters more than price.
Coverage and Free Cash Flow: A Well-Funded Payout
A quick look at the cash flow statement and the dividend looks fairly comfortable. In fiscal 2025, Gilead generated operating cash flow of $10.019 billion, spent $563 million on capital expenditures, and paid $4.003 billion in dividends. Free cash flow, in other words, covers the payout with room to spare.
GAAP net income for 2024 was only $480 million, hit by a large charge tied to an acquisition. Fiscal 2025 recovered to $8.51 billion in net income on revenue of $29.442 billion. The pattern repeated in the second quarter of 2026, when a $11.2 billion acquired in-process R&D charge from the Arcellx, Tubulis, and Ouro Medicines deals produced a quarterly net loss of $10.496 billion. Strip out the acquisition accounting, and management put underlying non-GAAP diluted EPS for the quarter at $2.27, with an illustrative full-year range of $8.50 to $8.85.
Second-quarter operating cash flow was still $3.573 billion. Gilead returned close to $1.4 billion to shareholders in the quarter, including $355 million in buybacks, and CFO Andrew Dickinson said the company returned roughly 49% of free cash flow to shareholders in the first half. That is the number that matters for dividend safety.
Raise Record: Small, Steady, Predictable
Gilead’s quarterly dividend history reads as follows: $0.75 in 2023, $0.77 in 2024, $0.79 in 2025, and $0.82 in 2026. The raises are modest but consistent, which is what a scorecard rewards. This is a compounder that treats the check as a commitment.
Patent Cliffs Explained in Plain English
A pharmaceutical dividend is only as durable as the drugs that fund it. Patents give a company a limited window of exclusive sales. When they expire, generic manufacturers enter, prices collapse, and revenue can drop sharply. That drop is called a patent cliff, or loss of exclusivity.
Gilead’s cash flow is concentrated in HIV. Second-quarter HIV sales were $5.7 billion, up 12% year-over-year, and Biktarvy alone contributed $3.8 billion. Concentration risk is real. The offset is time. Following patent settlements, the earliest generic Biktarvy entry has been pushed to April 2036, and no major loss of exclusivity is expected until 2036.
Pipeline: Building the Bridge to the Next Decade
PrEP sales doubled year over year and exceeded $1 billion in a quarter for the first time, with a total PrEP business run rate of $4 billion. The twice-yearly Yeztugo prevention therapy is tracking toward approximately $1 billion in full-year sales, and management reported that more than 70% of users returned for their six-month reinjection.
In oncology, Trodelvy revenue reached $457 million in the quarter, up 26% year over year, approaching a $2 billion run rate. Livdelzi in liver disease more than doubled to $167 million. The cell therapy franchise slipped 14% year over year against competition, with NitoCell targeting a PDUFA date of December 23, 2026.
CEO Daniel O’Day framed the strategy directly: “Clearly, our objective is still to diversify the business, but in two different ways, just to clarify. One is within virology, and the second one is outside of virology.”
Balance Sheet After the Deal Wave
As of the quarter ended June 30, 2026, Gilead reported cash and short-term investments of $3.179 billion, down from $7.628 billion at the end of the prior quarter. Total debt stood at $26.246 billion, with long-term debt of $23.832 billion. Total shareholder equity dropped to $11.828 billion following the IPR&D writedowns.
Leverage is elevated, but manageable given the operating cash flow profile. Dickinson said Gilead does not currently anticipate pursuing additional sizable M&A transactions during 2026, prioritizing integration.
Risks Worth Naming Out Loud
- Revenue concentration: HIV drives the profit engine, and Biktarvy drives HIV.
- Patent expirations: even with the extended runway to 2036, the eventual generic entry is a known event.
- Clinical and regulatory risk: BicLen, ISLEN, NitoCell, and the Tubulis ADC platform all carry trial and approval risk.
- Policy and pricing: management cited softer HIV treatment growth after Affordable Care Act tax subsidies were eliminated, and expects a return to 2% to 3% annual growth.
- Acquisition indigestion: the $11.2 billion in acquired IPR&D charges will keep GAAP earnings noisy.
Verdict: Does the Check Keep Clearing?
Grade: B+. The 0.0215 yield will not fund a retirement on its own, but the coverage is solid, the raise cadence is reliable, and the patent runway on the core HIV franchise stretches to 2036. Free cash flow of $10.019 billion against dividends of $4.003 billion in 2025 is the kind of cushion income investors want to see, and the whole point of a dividend ladder is never having to sell shares to live off the checks (we walked through how to build one in a free guide here). The pipeline, from Yeztugo to Trodelvy to NitoCell, is doing the work required to replace HIV revenue when the cliff eventually arrives.
For a retiree asking whether the check keeps clearing, the answer is yes. Gilead’s dividend is dependable.
Contact [email protected] for any questions or corrections.
Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.
